2026 Liver Nodule Consensus Interpretation: The "Liver Cancer Trio" Listed as the Core Serological Scheme for Differentiating Benign from Malignant Liver Nodules and Early Liver Cancer Screening

In February 2026, the "Expert Consensus on the Diagnosis, Treatment, and Management of Liver Nodules (2026 Edition)" was officially released. This authoritative document, led by the Infectious Disease Prevention and Control Branch of the Chinese Preventive Medicine Association and jointly developed by multidisciplinary experts in infectious diseases, hepatobiliary surgery, radiology, and other fields, systematically outlines the full-process standards for liver nodules from screening and diagnosis to treatment, providing programmatic guidance for precise clinical diagnosis and treatment. Among them, the "Liver Cancer Trio" — composed of alpha-fetoprotein (AFP), alpha-fetoprotein-L3 isoform (AFP-L3), and des-gamma-carboxy prothrombin (DCP/PIVKA-II) — has been explicitly listed as the core serological scheme for differentiating benign from malignant liver nodules and early liver cancer screening, with its clinical value highly recognized by multidisciplinary experts.

I. Core Insights of the Consensus: High Risk of Malignant Transformation in Liver Nodules, Shortcomings in Traditional Screening Methods

The consensus points out that liver nodules are a typical manifestation of chronic liver disease progression, with over 800,000 people worldwide dying each year from end-stage liver diseases such as cirrhosis and hepatocellular carcinoma (HCC). Among them, high-grade dysplastic nodules (HGDN) in the context of cirrhosis have a 5-year malignant transformation rate as high as 80%, making them definite precancerous lesions; LR-4 category nodules in the Liver Imaging Reporting and Data System (LI-RADS) classification have a progression rate to HCC of 30.9%–71.0%, and malignant transformation mostly occurs within the first 6 months of follow-up, making early identification urgently needed.

However, traditional screening models have significant limitations: ultrasound examination has a high missed diagnosis rate for tiny lesions <1 cm in diameter; a single AFP test shows false negatives in 32%–59% of liver cancer patients, which cannot meet early screening needs. Addressing this pain point, Consensus Recommendation 3 explicitly states: the combined use of AFP, AFP-L3, and DCP improves the sensitivity of early HCC screening; for suspected cases with negative AFP, AFP-L3 and DCP can serve as important supplementary detection indicators. This recommendation provides high-level evidence support for the clinical application of the Liver Cancer Trio.

II. Clinical Value of the Liver Cancer Trio: Three-Way Complementarity Building a Precise Diagnostic System

The combined application of the Liver Cancer Trio is not a simple superposition, but rather forms a complete diagnostic chain covering "early warning – missed diagnosis supplementation – risk stratification" through the complementarity between indicators. Its value is fully confirmed in the consensus:

1. Supplementing AFP-Negative Missed Diagnoses, Capturing "Silent Liver Cancer"

The consensus clarifies that a single AFP test has significant limitations, with approximately 32%–59% of HCC patients having persistently normal AFP levels. Compared with traditional AFP testing, DCP (PIVKA-II) has higher sensitivity (54% vs. 42%, respectively) and specificity (86% vs. 83%, respectively), and can effectively identify AFP-negative liver cancer cases, solving the core pain point of single-marker screening.

2. Ultra-Early Warning of Tiny Liver Cancer, Seizing the Intervention Window

AFP-L3 is one of the three glycoforms of AFP, derived exclusively from tumor tissue, and its proportion increases with the degree of carcinogenesis. The consensus mentions that AFP-L3 testing helps detect liver cancer <2 cm in diameter in high-risk populations, and can indicate the presence of liver cancer before imaging examinations become positive, securing valuable early intervention time for clinical practice.

3. Supporting Risk Assessment Models, Facilitating Precise Stratification

The Liver Cancer Trio is a core component of risk assessment models such as GALAD recommended by the consensus. This model integrates five key indicators — sex, age, AFP, AFP-L3, and DCP — for HCC monitoring and diagnosis. A large-scale study involving five medical centers in China showed that the GALAD model has an AUC value of 0.935 for diagnosing liver cancer, with a sensitivity of 83.78% and specificity of 88.69%, effectively distinguishing benign liver nodules from early liver cancer.

Clinical data show that the combined detection of the Liver Cancer Trio achieves an early liver cancer detection rate exceeding 85%, an improvement of more than 40% compared with single AFP testing, significantly increasing the 5-year survival rate of early liver cancer patients and becoming a key link in improving patient prognosis.

III. Hotgen Technology Empowerment: Precision Testing Aligned with Consensus Requirements

As an innovation pioneer in the field of in vitro diagnostics, Hotgen Biotech has developed a Liver Cancer Trio testing solution relying on core platforms such as glycan capture technology and magnetic microparticle chemiluminescence, perfectly meeting the clinical application requirements of the 2026 edition consensus. The solution adopts a "one-tube blood, one-stop testing" model: glycan capture technology can specifically recognize tumor-specific glycoform markers such as AFP-L3 with strong anti-interference capability; magnetic microparticle chemiluminescence technology offers high automation and fast detection speed, suitable for large-scale screening scenarios in medical institutions at all levels. The testing kits strictly follow consensus standards and have passed multicenter clinical validation, capable of precisely capturing indicator changes in early lesions and providing a reliable basis for differentiating benign from malignant liver nodules.

Hotgen Fully Automated Chemiluminescence Immunoassay System

Hotgen Fully Automated Chemiluminescence Immunoassay System

According to Consensus Recommendation 6, the following populations should include the Liver Cancer Trio in their routine screening plans to achieve dual protection of "serology + imaging":

1. Patients with cirrhosis caused by various etiologies;

2. Chronic HBV or hepatitis C virus carriers aged ≥30 years;

3. Those with a family history of cirrhosis or liver cancer;

4. Those with a clear history of exposure to carcinogenic toxins;

In terms of screening frequency: high-risk populations should be screened once every 6 months starting from age 40; extremely high-risk populations (those with cirrhosis, liver nodules, or a family history of liver cancer) should be monitored once every 3 months starting from age 30, to minimize the risk of malignant transformation.

References

(1) Infectious Disease Prevention and Control Branch of the Chinese Preventive Medicine Association. Expert Consensus on the Diagnosis, Treatment, and Management of Liver Nodules (2026 Edition) [J]. Chinese Journal of Hepatology, 2026, 34(1): 59-74.